170456-88-9

Upstream product

• 170456-83-4 1-tosyl-3-(R)-(-)-hydroxypyrrolidine 
• 16851-72-2 1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole 
• 70-55-3 toluene-4-sulfonamide 
• 73696-28-3 1-[(4-methylphenyl)sulfonyl]pyrrolidin-3-one 
• 62-55-5 thioacetamide 
• 170456-82-3 4-bromo-1-(p-toluenesulfonyl)pyrrolidin-3-one 

Downstream Products

• 773031-79-1 2-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole 
• 170456-89-0 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole 

Relevant academic research and scientific papers

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 1-CYCLOPROPYL-6,8-DIFLUORO-7-(2-SUBSTITUTED 4,6-DIHYDRO-1H-PYRROLOTHIAZOL-5-YL)-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID

Quinolone derivatives (9 and 10) substituted with bicyclothiazole (7) and (8) at C-7 position were synthesized.Bicyclothiazole derivatives (7 and 8) were prepared through 9 steps by way of the 4-bromo-3-oxopyrrolidine (16) was a key intermediate and intro